Bayer 2013 outlook slightly below market view
FRANKFURT Feb 28 (Reuters) - Germany's largest drugmaker Bayer gave a 2013 underlying earnings outlook that was slightly below analyst expectations amid fresh competition for one of its most promising new drugs.
Bayer, which celebrates its 150th anniversary this year, said it expected growth in adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) in the mid single-digit percentage range, where analysts had seen a gain of about 8 percent.
Fourth-quarter adjusted EBITDA rose 18.4 percent to 1.825 billion euros ($2.39 billion), in line with the average estimate in a Reuters poll.
Quarterly sales of 9.86 billion euros were slightly above expectations. ($1 = 0.7628 euros) (Reporting by Ludwig Burger and Frank Siebelt)
- iPhone comes out of a 'bygone era', reviewers hail bigger handset
- Scots' support for independence lags on eve of referendum |
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Fed may hint on rate-hike plan as it prepares for policy turn
- Islamic State campaign tests Obama's commitment to Mideast allies